The checkpoint inhibitor tislelizumab might reasonably be considered a better choice for hepatocellular carcinoma than sorafenib based on new analyses from a pivotal phase 3 trial presented at the 2023 American Society of Clinical Oncology Breakthrough Meeting. Although the overall survival advantage was not significant, the quality of life on this therapy is better, according to the newly released data.
In more detailed analyses of the RATIONALE-301 trial—which was first presented in 2022